|
CIGB-500 in acute myocardial infarction (AMIGOS study) |
|
CIGB-Mambisa/Abdala in convalescents |
|
CIGB2020- ARI elderly contacts |
|
CIGB500 in healthy volunteers |
|
CIMAbior® in CD20-positive B-cell Non-Hodgkin Lymphoma |
|
CIMAVax EGF in Lung Cancer in PHC. Phase IV |
|
CIMAvax-EGF in Bladder cancer |
|
CIMAvax-EGF in different maintenance schemes |
|
CIMAvax-EGF in patients at high risk of lung cancer |
|
CIMAvax-EGF vaccine Predictor Phase IV |
|
CIMAvax-EGF-Platelets-Adults- Lung Cancer |
|
CIMAvax-EGF/Lung cancer/Biomarkers/Prospective CT |
|
CIMAvax-EGF® in metastatic asymptomatic or mildly symptomatic Castration Resistant Prostate Cancer patients. Phase II-III Clinical Trial |
|
CIMAvax-EGF®-post-COVID19 convalescent with respiratory disorders-adults-Phase II (CORVAXCIM) |
|
CIMAvaxEGF in Non Small Cell Lung Cancer. Exploratory Study of Biomarkers |
|
CIMAvax®-EGF in patients with moderate-severe chronic obstructive pulmonary disease (COPD) |
|
CITOPROT-III |
|
Clinical evaluation of the effect anti-inflammatory of the extract of Mangifera indica L. (Vimang®) in patients with diagnosis of Bronchial Asthma |
|
Clinical Trial Heberbiovac HB vaccine Material Reference Batch |
|
Clinical trial to evaluate the safety, reactogenicity and immunogenicity of the vax-TyVi vaccine in volunteers between 18 and 20 years of age. |
